Video #1 Aug. 29, 2011(Bloomberg) -- Uri Landesman, president of Platinum Management LLC, talks about the outlook for consolidation in the biotechnology industry. Landesman also discusses prospects for Echo Therapeutics Inc. and his investment strategy. He speaks with Pimm Fox on Bloomberg Television's "Taking Stock." (Source: Bloomberg)
Video #2 Dec. 27, 2011 (Bloomberg) -- Uri Landesman, managing general parter of Platinum Partners LLP, talks about the outlook for mergers and acquisitions in the pharmaceutical and biotechnology industries in 2012, and his recommendation of Neoprobe Corp. and Echo Therapeutics Inc. He speaks with Deirdre Bolton on Bloomberg Television's "Money Moves." (Source: Bloomberg)
NAVB - Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation (NEOP) , is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company's radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent. In January 2012, the Company executed an option agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IACFT Injection, also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson's disease, movement disorders and dementia. In August 2011, the Company sold its gamma detection device line of business (the GDS Business) to Devicor Medical Products, Inc.
News 
Market Data 
Discover 
